Idexx Laboratories INC /DE Form 4 insider transactions

Executive Vice President Michael Perkins Johnson reports transactions involving IDEXX Laboratories Inc. stock, including option grants and restricted stock unit vesting.

Executive Vice President Nimrata Hunt reports acquisition and disposal of Idexx Laboratories stock and stock options.

Executive Vice President George Fennell of Idexx Laboratories reports the grant of stock options and vesting of restricted stock units.

Executive Vice President Michael G. Erickson reports transactions involving Idexx Laboratories Inc. stock, including the acquisition and disposal of common stock and derivative securities.

Michael G. Erickson, Executive Vice President of IDEXX Laboratories, exercised stock options to acquire 1,544 shares of common stock at $67.85 per share.

Executive Vice President George Fennell of IDEXX Laboratories reported the exercise of stock options and subsequent sale of shares on February 7th and 10th, 2025.

M. Anne Szostak, a director at IDEXX Laboratories Inc, sold 3,000 shares of common stock at a price of $465.945 on February 7, 2025.

Director Sophie V. Vandebroek of IDEXX Laboratories reported the disposition of 344 shares and the acquisition of 224 shares of common stock on November 27, 2024.

Jonathan Ayers, a director at Idexx Laboratories, reported changes in his beneficial ownership of the company's common stock due to transactions involving Grantor Retained Annuity Trusts (GRATs).

M. Anne Szostak, a director at IDEXX Laboratories, reported gifting and selling shares of common stock, according to a recent SEC Form 4 filing.

Executive Vice President Michael Schreck reported the vesting of restricted stock units and subsequent disposition of shares to cover tax obligations.

Executive Vice President Martin Alexander Smith of IDEXX Laboratories reports the acquisition and disposal of company stock on September 1, 2024, according to a Form 4 filing.

Brian P. McKeon, EVP, CFO and Treasurer of IDEXX Laboratories, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Jonathan Mazelsky, President and CEO of IDEXX Laboratories, reported the vesting of restricted stock units and associated stock transactions.

Director Bruce L. Claflin reported the sale of 200 shares of IDEXX Laboratories Inc. common stock on May 17, 2024.

Director Sophie V. Vandebroek reports the acquisition of stock options and vesting of restricted stock units (RSUs) in IDEXX Laboratories.

M. Anne Szostak, a director at IDEXX Laboratories Inc., reports transactions involving common stock and derivative securities, including option grants and restricted stock units.

Director Sam Samad reports acquisition of stock options and deferred stock units in IDEXX Laboratories.

Lawrence D. Kingsley, a director at IDEXX Laboratories, reported the exercise of stock options and the grant of additional stock options and restricted stock units.

Director Daniel M. Junius reported the acquisition of stock options and restricted stock units in IDEXX Laboratories, Inc. on May 6, 2024.

Director Stuart Essig reports the acquisition of stock options and restricted stock units (RSUs) in IDEXX Laboratories, along with the disposal of shares upon RSU vesting.

Director Asha Collins reports the acquisition and disposal of IDEXX Laboratories Inc. stock and derivative securities.

Bruce L. Claflin, a director at IDEXX Laboratories, reported the acquisition of stock options and deferred stock units.

Director Irene Chang Britt reports the acquisition and disposal of IDEXX Laboratories stock and derivative securities, including stock options and deferred/restricted stock units, as per Form 4 filing.

Director Jonathan Ayers reports transactions involving IDEXX Laboratories stock, including option grants and restricted stock unit vesting.

Executive Vice President James F. Polewaczyk reports exercising stock options and selling shares of IDEXX Laboratories Inc.

Director Sophie V. Vandebroek reports the exercise of stock options and subsequent sale of shares in Idexx Laboratories.

Jonathan Mazelsky, President and CEO of IDEXX Laboratories, reported a gift of 550 shares of common stock on February 29, 2024.